Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience.
Joseph Peill, Katie Trinci, Hannes Kettner, Lea J. Mertens, Leor Roseman, Christopher Timmermann, Fernando E. Rosas, Taylor Lyons, Robin Carhart-Harris
Journal of Psychopharmacology January 5, 2022 DOI: 10.1177/02698811211066709 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Scale development and validation study Peer reviewed |
|---|---|
| Sample size | 886 |
| Population | Participants reporting a planned psychedelic experience; 279 participants from a separate global psychedelic survey for validation |
| Measures | Psychological Insight Scale (PIS), Therapeutic-Realizations Scale |
| Keywords | Psychedelic research Psychological insight Psychometric scale Therapeutic potential |
| Citations | 135 |
| Key points | The Psychological Insight Scale (PIS) showed a single principal component explaining 73.57% of the variance and high internal consistency (average Cronbach's alpha = 0.94). PIS scores significantly mediated the relationship between emotional breakthrough and long-term well-being, leading the authors to argue that insight is a key mediator of long-term psychological outcomes following a psychedelic experience. |
Abstract
Introduction: As their name suggests, 'psychedelic' (mind-revealing) compounds are thought to catalyse processes of psychological insight; however, few satisfactory scales exist to sample this. This study sought to develop a new scale to measure psychological insight after a psychedelic experience: the Psychological Insight Scale (PIS).
Methods: The PIS is a six- to seven-item questionnaire that enquires about psychological insight after a psychedelic experience (PIS-6) and accompanied behavioural changes (PIS item 7). In total, 886 participants took part in a study in which the PIS and other questionnaires were completed in a prospective fashion in relation to a planned psychedelic experience. For validation purposes, data from 279 participants were analysed from a non-specific 'global psychedelic survey' study.
Results: Principal components analysis of PIS scores revealed a principal component explaining 73.57% of the variance, which displayed high internal consistency at multiple timepoints throughout the study (average Cronbach's α = 0.94). Criterion validity was confirmed using the global psychedelic survey study, and convergent validity was confirmed via the Therapeutic-Realizations Scale. Furthermore, PIS scores significantly mediated the relationship between emotional breakthrough and long-term well-being.
Conclusion: The PIS is complementary to current subjective measures used in psychedelic studies, most of which are completed in relation to the acute experience. Insight - as measured by the PIS - was found to be a key mediator of long-term psychological outcomes following a psychedelic experience. Future research may investigate how insight varies throughout a psychedelic process, its underlying neurobiology and how it impacts behaviour and mental health.
Citations in the library
Cited by 120
- Canalization and plasticity in psychopathology Neuropharmacology December 27, 2022
- Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder. Journal of Psychiatric Research May 1, 2023
- Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. Journal of Psychopharmacology August 1, 2022
- The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder PLoS One March 14, 2024
- Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020 Journal of Psychopharmacology March 6, 2023
and 115 more in the library
Cites 50
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology November 8, 2017
and 45 more in the library